Chipscreen Biosciences, Ltd.

This study tested a combination of two drugs, tucidinostat and tislelizumab, as the first treatment for people with a certain type of advanced lung cancer (non-small cell lung cancer that is PD-L1 positive). The trial involved 118 adults who had not received prior cancer therapy …

This study tested whether adding an oral drug called tucidinostat to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called double-expressor DLBCL. The trial involved 423 newly diagnosed adults and measured how long they lived without the cancer g…